Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Yuxin Xu; Wenyun Zheng; Tianwen Wang; Ping Wang; Ling Zhu; Xingyuan Ma

doi:10.1016/j.biopha.2011.12.004

Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Yuxin Xu, Wenyun Zheng, Tianwen Wang, Ping Wang, Ling Zhu, Xingyuan Ma

Bioproducts and Biosystems Engineering

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.

Original language	English (US)
Pages (from-to)	368-372
Number of pages	5
Journal	Biomedicine and Pharmacotherapy
Volume	66
Issue number	5
DOIs	https://doi.org/10.1016/j.biopha.2011.12.004
State	Published - Jul 2012

Bibliographical note

Funding Information:
This work was supported by the National Natural Science Foundation (30873190), the National Science Research Project “Significant New Drugs Created” of Eleventh Five-year Plan (2009ZX09103-693) and Key for Fundamental and Interdisciplinary Research of Chinese Ministry (WK0913002).

Keywords

Breast cell lines
Chemotherapeutic agent
Enhancing sensitivity
Genetic protein TmSm(T34A)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.biopha.2011.12.004

OpenUrl availability

Full text

Cite this

@article{b6f7cf1e33dd40788d297d9eeddc6199,

title = "Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin",

abstract = "In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.",

keywords = "Breast cell lines, Chemotherapeutic agent, Enhancing sensitivity, Genetic protein TmSm(T34A)",

author = "Yuxin Xu and Wenyun Zheng and Tianwen Wang and Ping Wang and Ling Zhu and Xingyuan Ma",

note = "Funding Information: This work was supported by the National Natural Science Foundation (30873190), the National Science Research Project “Significant New Drugs Created” of Eleventh Five-year Plan (2009ZX09103-693) and Key for Fundamental and Interdisciplinary Research of Chinese Ministry (WK0913002).",

year = "2012",

month = jul,

doi = "10.1016/j.biopha.2011.12.004",

language = "English (US)",

volume = "66",

pages = "368--372",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson",

number = "5",

}

TY - JOUR

T1 - Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

AU - Xu, Yuxin

AU - Zheng, Wenyun

AU - Wang, Tianwen

AU - Wang, Ping

AU - Zhu, Ling

AU - Ma, Xingyuan

N1 - Funding Information: This work was supported by the National Natural Science Foundation (30873190), the National Science Research Project “Significant New Drugs Created” of Eleventh Five-year Plan (2009ZX09103-693) and Key for Fundamental and Interdisciplinary Research of Chinese Ministry (WK0913002).

PY - 2012/7

Y1 - 2012/7

N2 - In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.

AB - In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.

KW - Breast cell lines

KW - Chemotherapeutic agent

KW - Enhancing sensitivity

KW - Genetic protein TmSm(T34A)

UR - http://www.scopus.com/inward/record.url?scp=84864021256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864021256&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2011.12.004

DO - 10.1016/j.biopha.2011.12.004

M3 - Article

C2 - 22560635

AN - SCOPUS:84864021256

SN - 0753-3322

VL - 66

SP - 368

EP - 372

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

IS - 5

ER -

Genetic protein TmSm(T34A) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this